Released Nov 9, 2026, after the close
10-Q filed Nov 10, 2026, 41 days after period end · 0001104659-26-125236
| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | — | $4.60M | $5.61M | — |
| Net Income | -$4.76M | -$12.42M | -$11.56M | -$11.25M |
| EPS Diluted |
Maxcyte, Inc. · CIK 1287098 · Engraved from SEC EDGAR
| -$0.05 |
| -$0.12 |
| -$0.11 |
| -$0.11 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
MaxCyte agreed on November 9, 2026 to acquire all outstanding equity of Akron BioProducts LLC for $105.0 million in cash, 20,639,733 shares of common stock, and $20.0 million in guaranteed deferred cash payments.¶1¶2¶3
The closing is expected before the end of 2026, subject to HSR waiting period expiration and Nasdaq listing approval, and is not subject to a financing condition or stockholder approval; the stock consideration has a six-month lock-up.¶4
MaxCyte reported third quarter 2026 total revenue of $10.2 million, an increase of 49% over the third quarter of 2025, and a net loss of $4.8 million compared to $12.4 million a year earlier.¶5¶6
MaxCyte raised its full year 2026 total revenue guidance to at least $34.5 million, excluding the impact of the Akron acquisition.¶7¶8
The 20,639,733 shares of common stock will be issued to the Sellers at the Closing in reliance on the Section 4(a)(2) exemption from registration.¶9